IQWIG Finds No Added Benefit With Novo’s Xultophy Or Lundbeck’s Brintellix

This article was originally published in The Pink Sheet Daily

05 Aug 2015
News

John Davis john.davis@informa.com

Executive Summary

The preliminary evaluation now goes to Germany’s Federal Joint Committee to make a final decision on the products’ usefulness in the country’s health care system, and their future pricing.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Germany

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Germany Comparative Effectiveness

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS078881

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS078881

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

IQWIG Finds No Added Benefit With Novo’s Xultophy Or Lundbeck’s Brintellix

News

Executive Summary

Related Content

Takeda Aims To Turn Brintellix Into CNS Cornerstone, Arm-In-Arm With Lundbeck

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert